Backgrounder

Type 2 Diabetes Subgroup Analysis

biomea FUSION

Diabetes Subgroup Clustering Provide Validated Biomarkers

Pre-Diabetes

Initial Decline in Glycemic Control
Increasing HbA1c, Increasing Insulin Resistance
Decreasing beta cell numbers and function

T2D

HbA1c
HOMA-B
HOMA-IR
BMI
Age

18%

SIDD = Severe Insulin Deficient Diabetes
Low insulin secretion, poor metabolic control, increased risk of retinopathy and neuropathy

15%

SIRD = Severe Insulin Resistant Diabetes
Insulin resistance, obesity, late onset, increased risk of nephropathy and fatty liver

22%

MOD = Mild Obesity-Related Diabetes
Obesity, early onset

39%

MARD = Mild Age-Related Diabetes
Late onset, low risk of complications

T1D

Initial Diagnosis/Disease – Stage 2/Stage 3
Increasing HbA1c, Initial Reduction in Insulin
Significant Decrease in beta cell numbers

Targeted Patient Population for BMF-219



Adjusted from Ahlqvist et al. Diabetes 2020;69:2086–2093 | https://doi.org/10.2337/dbi20-0001

Song et al. Front Endocrinol (Lausanne). 2022 Jul 27:13:927661. doi: 10.3389/fendo.2022.927661. eCollection 2022.

According to Diabetes Subgroup Clusters, 50%-60% T2D Patients are Beta-Cell/Insulin Deficient (– Potential Population that Benefits the Most from BMF-219)

T2D Patient Distribution based on US Population



	Patient Distribution (%)	Age (years), Median	HbA1c (mmol/mol) Median	BMI (kg/m^2) Median	HOMA2-B (%) Median	HOMA2-IR (%) Median
SIDD	14.3%	55 (48-61)	67 (64-74)	29 (27-32)	49 (38-59)	2.3 (1.8-2.8)
MARD	45.4%	61 (55-66)	53 (49-56)	29 (26-31)	64 (53-76)	2.3 (1.8-2.7)
MOD	32.4%	47 (41-52)	55 (51-61)	36 (33-40)	74 (59-89)	3.1 (2.4-3.7)
SIRD	7.9%	59 (53-66)	53 (48-60)	34 (30-38)	101 (87-121)	4.0 (3.4-4.7)

*SIDD and MARD are characterized by low BMI, low beta-cell function/insulin production, and low insulin resistance.

Adjusted from Dennis et al. Lancet Diabetes Endocrinol. 2019 Jun; 7(6): 442–451; Zou et al. Lancet Diabetes Endocrinol. 7(1), 9–11 (2019)

DDZ Diabetes Cluster Identification Online Tool

German Diabetes Center

Input: Age at diagnosis, BMF, fasting plasma glucose, fasting C-Peptide, HbA1c, sex

Input

DDZ Diabetes-Cluster-Tool

Deutsch (https://diabetescalculator.ddz.de/diabetescluster)

GAD-Antibodies

Not Present

Note: When GAD-Antibodies are present the person is automatically assigned to the subtype 1/SAID.

Age at diagnosis (years)

55

BMI (kg/m²)

26.9

Plasma glucose unit (mmol/l or mg/dl)

mg/dl

Fasting plasma glucose (fasting blood sugar)

227

C-Peptide unit (ng/ml, nmol/l or pmol/l)

ng/ml

Fasting C-Peptide

3.63

HbA1c (%)

10.1

This person most resembles the diabetes subtype:

2/SIDD



The **DDZ Diabetes-Cluster-Tool** assigns people with diabetes to one of the five diabetes subtypes (diabetes clusters). In addition, it graphically depicts the degree of similarity to each of the five subtypes.

The diabetes subtypes are:

- 1/SAID: Severe autoimmune diabetes
- 2/SIDD: Severe insulin-deficient diabetes
- 3/SIRD: Severe insulin-resistant diabetes
- 4/MOD: Mild obesity-related diabetes
- 5/MARD: Mild age-related diabetes

References

Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., ... & Groop, L. (2018). Novel

DDZ Diabetes Cluster Tool [DDZ Diabetes-Cluster-Tool]

biomea FUSION We Aim to Cure™

Five Reproducible Clusters leading to Precision Medicine in Diabetes



Cluster 1: Severe Autoimmune Diabetes (SAID)
Cluster 2: Severe Insulin-Deficient Diabetes (SIDD)
Cluster 3: Severe Insulin-Resistant Diabetes (SIRD)
Cluster 4: Mild Obesity Diabetes (MOD)
Cluster 5: Mild Age-Related Diabetes (MARD)

biomea FUSION™ We Aim to Cure™

Ahlquist et al. Lancet Diabetes Endocrinol 2018; 6: 361–69

Key Trait & Variant Associations for the 5 Subgroup Clusters

	Cluster name	Key traits	Key genetic loci	Suspected mechanism
Insulin Deficiency	 Beta Cell	↓ **Fasting insulin**, Insulin response to glucose stimulation ↑ **Proinsulin**	*MTNR1B, HHEX, TCF7L2, SLC30A8, HNF1A, HNF1B*	**Insulin processing/ secretion**
Insulin Deficiency	 Proinsulin	↓ **Fasting insulin,** Insulin response to glucose stim ↓ **Proinsulin**	*ARAP1, SPRY2, DGKB*	**Insulin synthesis**
Insulin Resistance	 Obesity	↑ **Fasting insulin** ↑ **BMI, %Body Fat,** Waist Circ, Hip Circ	*FTO, MC4R, NRXN3*	**Obesity-mediated IR**
Insulin Resistance	 Lipodystrophy	↑ **Fasting insulin** ↓ **BMI, %Body Fat,** HDL	*IRS1, GRB14, PPARG, LYPLAL1, ANKRD55*	**Fat distribution- mediated IR**
Insulin Resistance	 Liver/Lipid	↑ **Fasting insulin** ↓ **Triglycerides,** palmitoleic acid, linolenic acid	*GCKR, TM6SF2, HLA.DQA1, PNPLA3*	**Liver/lipid metabolism**

Udler et al. PLoS Med 2018 Sep 21;15(9):e1002654

Significant Number of Diabetes Patients Are Insulin-Dependent

~30% Severe Insulin-Deficient Diabetes Patients (SIID) are Insulin Dependent by Year 5 of Diagnosis

~90% of the Severe Insulin Deficient Diabetes Patients are Metformin Dependent by Year 2 of Diagnosis



Ahlquist et al. Lancet Diabetes Endocrinol 2018; 6: 361–69

Diabetes Subgroup Clusters Provide a More Precise Clinically Useful Stratification towards Precision Medicine in Diabetes

Chronic Kidney Disease



End-Stage Renal Disease



Severe insulin-resistance diabetes patients have the highest risk of developing chronic kidney disease and end-stage renal disease.

- Cluster 1: Severe autoimmune diabetes (SAID)
- Cluster 2: Severe insulin-deficient diabetes (SIDD)
- Cluster 3: Severe insulin-resistant diabetes (SIRD)
- Cluster 4: Mild obesity diabetes (MOD)
- Cluster 5: Mild age-related diabetes (MARD)

Ahlquist et al. Lancet Diabetes Endocrinol 2018; 6: 361–69

Relevant Literature

Novel subgroups of adult-onset diabetes and there association with outcomes: a data-driven cluster analysis of six variables
Emma Ahlqvist et al. 2018 May;6(5):361-369. doi: 10.1016/S2213-8587(18)30051-2. Epub 2018 Mar 5.

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
John M Dennis, Beverley M Shields, William E Henley, Angus G Jones, Andrew T Hattersley. Lancet Diabetes Endocrinol 2019; 7: 442–51

Subtypes of Type 2 Diabetes Determined From Clinical Parameters
Emma Ahlqvist,1 Rashmi B. Prasad,1 and Leif Groop. Diabetes 2020;69:2086–2093 | https://doi.org/10.2337/dbi20-0001

Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult-onset diabetes mellitus: A perspective
Hayato Tanabe, Hiroaki Masuzaki, Michio Shimabukuro. 2021 Oct:180:109067. doi: 10.1016/j.diabres.2021.109067. Epub 2021 Sep 23.

The Identification of Diabetes Mellitus Subtypes Applying Cluster Analysis Techniques: A Systematic Review
Antonio Sarría-Santamera, Binur Orazumbekova, Tilektes Maulenkul, Abduzhappar Gaipov and Kuralay Atageldiyeva
PMID:**33353219,** PMCID: PMC7766625, DOI: 10.3390/ijerph17249523

Etiologies underlying subtypes of longstanding type 2 diabetes
Riad Bayoumi*, et al., 2024 May 28;19(5):e0304036. doi: 10.1371/journal.pone.0304036. eCollection 2024.

Contact:
Chunyi Zhao, PhD
Associate Director of Investor Relations & Corporate Development
czhao@biomeafusion.com
T: +1 650-460-7759

THANK YOU

biomea FUSION™ We Aim to Cure™

Biomea Fusion
900 Middlefield Road, 4th floor
Redwood City, CA, 94063
biomeafusion.com